Xeris Biopharma Holdings (LTS:0A8E) Institutional Ownership : 19.24% (As of Jun. 20, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Xeris Biopharma Holdings Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Xeris Biopharma Holdings's institutional ownership is 19.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Xeris Biopharma Holdings's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Xeris Biopharma Holdings's Float Percentage Of Total Shares Outstanding is 97.58%.

Xeris Biopharma Holdings Institutional Ownership Historical Data

The historical data trend for Xeris Biopharma Holdings's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Institutional Ownership Chart

Xeris Biopharma Holdings Historical Data

The historical data trend for Xeris Biopharma Holdings can be seen below:

	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-02-29	2024-03-31	2024-04-30	2024-05-31
Institutional Ownership	22.17	23.45	23.30	20.54	18.95	19.40	20.01	19.43	19.24	19.24

Xeris Biopharma Holdings Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Xeris Biopharma Holdings (LTS:0A8E) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (LTS:0A8E) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

XERS:USA 2B30:Germany

Address

180 North LaSalle Street, Suite 1600, Chicago, IL, USA, 60601

Website

https://www.xerispharma.com

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

Xeris Biopharma Holdings (LTS:0A8E) Headlines

No Headlines